Antimicrobial compositions

1. An intravenous pharmaceutical composition comprising:

(a) a quinolone carboxylic acid derivative or a pharmaceutically acceptable salt or ester thereof, wherein the quinolone carboxylic acid derivative corresponds to the following compound (A):

(b) meglumine;

(c) a SBE-7-β-CD; and

(d) disodium EDTA.

2. The intravenous pharmaceutical composition according to claim 1 , wherein the quinolone carboxylic acid derivative is a D-glucitol,1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylate (salt).

3. The intravenous pharmaceutical composition according to claim 2 wherein said quinolone carboxylic acid derivative is a crystalline D-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylate (salt) characterized, when measured at about 25° C. with Cu-Ka radiation, by the powder diffraction pattern shown in FIG. 1 .

4. The intravenous pharmaceutical composition according to claim 1 , wherein the quinolone carboxylic acid derivative has a measurable improvement in solubility compared to the quinolone carboxylic acid derivative in water, and/or the composition has improved stability, and/or the composition provides a measurable enhancement in venous toleration.

5. The intravenous pharmaceutical composition according to claim 1 which is in the form of a lyophile.

6. The intravenous pharmaceutical composition according to claim 1 , wherein the cyclodextrin comprises from 0.01% to 50% by weight of the composition.

7. The intravenous pharmaceutical composition according to claim 6 , wherein the cyclodextrin comprises from 10% to 30% by weight of the composition.

8. The intravenous pharmaceutical composition according to claim 1 , wherein the composition has a pH from 7 to 11.

9. The intravenous pharmaceutical composition according to claim 8 , wherein the composition has a pH from 8 to 10.

10. The intravenous pharmaceutical composition according to claim 9 , wherein the composition has a pH from 8.5 to 9.5.

11. The intravenous pharmaceutical composition according to claim 10 , wherein the composition has a pH from 8.8 to 9.2.

12. The intravenous pharmaceutical composition according to claim 11 , wherein the composition has a pH of 9.0.

13. An intravenous pharmaceutical composition comprising:

(a) from 100 mg to 500 mg of delafloxacin,

(b) from 15 mg to 125 mg meglumine,

(c) from 500 mg to 5000 mg of a SBE-7-β-CD; and

(d) from 0 mg to 4 mg disodium EDTA.

14. The intravenous pharmaceutical composition according to claim 13 comprising:

(a) 100 mg of delafloxacin;

(b) 19.52 mg of meglumine;

(c) 800 mg of the SBE-7-β-CD; and

(d) 0.44 mg of disodium EDTA.

15. The intravenous pharmaceutical composition according to claim 13 comprising:

(a) 300 mg of delafloxacin;

(b) 58.56 mg of meglumine;

(c) 2400 mg of the SBE-7-β-CD; and

(d) 1.32 mg of disodium EDTA.

16. The intravenous pharmaceutical composition according to claim 13 comprising:

(a) 500 mg of delafloxacin;

(b) 97.6 mg of meglumine;

(c) 4000 mg of the SBE-7-β-CD; and

(d) 2.2 mg of disodium EDTA.

17. The intravenous pharmaceutical composition according to claim 13 which is in the form of a lyophile.

18. The intravenous pharmaceutical composition according to claim 13 , wherein the quinolone carboxylic acid derivative has a measurable improvement in solubility compared to the quinolone carboxylic acid derivative in water, and/or the composition has improved stability, and/or the composition provides a measurable enhancement in venous toleration.

19. The intravenous pharmaceutical composition according to claim 13 , wherein the composition has a pH from 7 to 11.

20. An intravenous pharmaceutical composition comprising:

(a) from 100 mg to 500 mg of delafloxacin meglumine,

(b) from 15 mg to 125 mg meglumine,

(c) from 500 mg to 5000 mg of the SBE-7-β-CD; and

(d) from 0 mg to 4 mg disodium EDTA.